Publications by authors named "Kimberly D Allman"

Claim this Profile
A
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Pedro C Barata, Alexander Chehrazi-Raffle, Kimberly D Allman, Aviva Asnis-Alibozek, Vijay Kasturi

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
Ruby Gupta, Moshe Chaim Ornstein, Hong Li, Kimberly D Allman, Laura S Wood

Clin Genitourin Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Anita Gul, Tyler F Stewart, Charlene M Mantia, Neil J Shah, Emily Stern Gatof, Kimberly D Allman

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Moshe C Ornstein, Sumanta K Pal, Laura S Wood, Jackie M Tomer, Brian P Hobbs, Kimberly D Allman

Lancet Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario.
Kimberly D Allman, Joanne C Ryan, Andrew Clair, Sarah Yenser-Wood

J Adv Pract Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
Moshe C Ornstein, Cassandra Calabrese, Laura S Wood, Elizabeth Kirchner, Pamela Profusek, Kimberly D Allman

Clin Genitourin Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
Moshe C Ornstein, Laura S Wood, Brian P Hobbs, Kimberly D Allman, Allison Martin

J Immunother Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
Yu-Wei Chen, Moshe C Ornstein, Laura S Wood, Kimberly D Allman, Allison Martin

Urol Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
Haris Zahoor, Pedro C Barata, Xuefei Jia, Allison Martin, Kimberly D Allman

J Immunother Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
Moshe C Ornstein, Laura S Wood, Paul Elson, Kimberly D Allman, Jennifer Beach

J Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis